Immunic (IMUX) Common Equity (2013 - 2026)

Immunic has reported Common Equity for 14 years, with the latest figure at $151.2 million in Q1 2026.

• Quarterly Common Equity rose 2960.47% year-over-year to $151.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $151.2 million (up 2960.47% YoY) and the FY2025 annual result came in at -$6.7 million, down 136.21% from the prior year.
• Common Equity advanced to $151.2 million in Q1 2026 per IMUX's latest filing, from -$6.7 million in the prior quarter.
• Over five years, Common Equity peaked at $151.2 million in Q1 2026 and troughed at -$6.7 million in Q4 2025.
• A 5-year average of $65.7 million and a median of $63.6 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2025 and 2026: Common Equity slumped 136.21% in 2025, then surged 2960.47% in 2026.
• Over 5 years, Common Equity stood at $113.7 million in 2022, then tumbled by 74.55% to $28.9 million in 2023, then tumbled by 36.3% to $18.4 million in 2024, then plunged by 136.21% to -$6.7 million in 2025, then soared by 2366.34% to $151.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $151.2 million, -$6.7 million, and $10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.